Acadia Pharmaceuticals Posts Q4 Earnings, Nuplazid & Daybue Drive Revenue Growth

Acadia Pharmaceuticals reported Q4 2025 earnings per share of 16 cents, beating the Zacks Consensus Estimate of 12 cents. Total revenues were $284 million, missing the consensus estimate of $293 million. Net product revenues from Nuplazid and Daybue increased 9% YoY, driven by contributions from Daybue and growth in Nuplazid's market share. The company expects total revenues of $1.27 billion to $1.32 billion in 2026.